title: Phase II study of mitozolomide in advanced soft tissue sarcoma of adults: the EORTC Soft Tissue and Bone Sarcoma Group.
authors.affiliation: Department of Internal Medicine, The Netherlands Cancer Institute, Amsterdam.
authors.forename: R
authors.initials: R
authors.lastname: Somers
authors.forename: A
authors.initials: A
authors.lastname: Santoro
authors.forename: J
authors.initials: J
authors.lastname: Verweij
authors.forename: P
authors.initials: P
authors.lastname: Lucas
authors.forename: J
authors.initials: J
authors.lastname: Rouëssé
authors.forename: T
authors.initials: T
authors.lastname: Kok
authors.forename: A
authors.initials: A
authors.lastname: Casali
authors.forename: C
authors.initials: C
authors.lastname: Seynaeve
authors.forename: D
authors.initials: D
authors.lastname: Thomas
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; C040369:mitozolomide